Sevoflurane acts as an antidepressant by suppression of GluN2D‐containing NMDA receptors on interneurons
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16420 ↗At a glance
Journal article in British Journal of Pharmacology, 2024. Written by Fei Guo and 15 co-authors. Institution: Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Department of Anesthesiol…. Major MEDLINE topics: Receptors, N-Methyl-D-Aspartate, Sevoflurane, Antidepressive Agents, Interneurons. Cited 17 times so far (Crossref); 67 references. Funded by: National Natural Science Foundation of China, National Major Scientific and Technological Special Project for 'Significant New Drugs Development', Natural Science Foundation of Shanghai.
Abstract (original language)
Background and Purpose Sevoflurane, a commonly used inhaled anaesthetic known for its favourable safety profile and rapid onset and offset, has not been thoroughly investigated as a potential treatment for depression. In this study, we reveal the mechanism through which sevoflurane delivers enduring antidepressant effects. Experimental Approach To assess the antidepressant effects of sevoflurane, behavioural tests were conducted, along with in vitro and ex vivo whole‐cell patch‐clamp recordings, to examine the effects on GluN1–GluN2 incorporated N ‐methyl‐ d ‐aspartate (NMDA) receptors (NMDARs) and neuronal circuitry in the medial prefrontal cortex (mPFC). Multiple‐channel electrophysiology in freely moving mice was performed to evaluate sevoflurane's effects on neuronal activity, and GluN2D knockout ( grin2d −/− ) mice were used to confirm the requirement of GluN2D for the antidepressant effects. Key Results Repeated exposure to subanaesthetic doses of sevoflurane produced sustained antidepressant effects lasting up to 2 weeks. Sevoflurane preferentially inhibited GluN2C‐ and GluN2D‐containing NMDARs, causing a reduction in interneuron activity. In contrast, sevoflurane increased action potentials (AP) firing and decreased spontaneous inhibitory postsynaptic current (sIPSC) in mPFC pyramidal neurons, demonstrating a disinhibitory effect. These effects were absent in grin2d −/− mice, and both pharmacological blockade and genetic knockout of GluN2D abolished sevoflurane's antidepressant actions, suggesting that GluN2D is essential for its antidepressant effect. Conclusion and Implications Sevoflurane directly targets GluN2D, leading to a specific decrease in interneuron activity and subsequent disinhibition of pyramidal neurons, which may underpin its antidepressant effects. Targeting the GluN2D subunit could hold promise as a potential therapeutic strategy for treating depression.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Department of Anesthesiology, Clinical and Translational Research Center, Shanghai First Matern…
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Institute for Cognitive Neurodynamics, East China University of Science and Technology, Shanghai, China.
- School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China.
- Institute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China.
ORCID profiles: Yang Li, Zhiqiang Liu
Funding
- National Natural Science Foundation of China
- National Major Scientific and Technological Special Project for 'Significant New Drugs Development'
- Natural Science Foundation of Shanghai
- Program of Shanghai Academic Research Leader
- Shanghai Science and Technology Commission
- Shanghai Municipal Health Commission
- Chinese Academy of Sciences
- Natural Science Foundation of Shanghai Municipality
Cite
APA
Guo, F., Zhang, B., Shen, F., Li, Q., Song, Y., Li, T., Zhang, Y., Du, W., Li, Y., Liu, W., Cao, H., Zhou, X., Zheng, Y., Zhu, S., Li, Y., & Liu, Z. (2024). Sevoflurane acts as an antidepressant by suppression of GluN2D‐containing NMDA receptors on interneurons. British Journal of Pharmacology. https://doi.org/10.1111/bph.16420
Vancouver
Guo F, Zhang B, Shen F, Li Q, Song Y, Li T, et al. Sevoflurane acts as an antidepressant by suppression of GluN2D‐containing NMDA receptors on interneurons. British Journal of Pharmacology. 2024. doi:10.1111/bph.16420
BibTeX
@article{Guo2024,
author = {Guo, Fei and Zhang, Bing and Shen, Fuyi and Li, Qian and Song, Yingcai and Li, Tianyu and Zhang, Yongmei and Du, Weijia and Li, Yuanxi and Liu, Wei and Cao, Hang and Zhou, Xianjin and Zheng, Yinli and Zhu, Shujia and Li, Yang and Liu, Zhiqiang},
title = {Sevoflurane acts as an antidepressant by suppression of GluN2D‐containing NMDA receptors on interneurons},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16420}
}
EUVIMED